ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2025-11-04 05:44Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.08% on November 4, 2023, despite a year-to-date decline of 19.62% [1][2]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is located in Jiangbei District, Chongqing. The company specializes in the research, production, and sales of vaccines and biological products [1]. - The revenue composition of Zhifei Biological includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 76.27 billion yuan, a year-on-year decrease of 66.53%. The net profit attributable to the parent company was -12.06 billion yuan, reflecting a year-on-year decline of 156.10% [2]. - The company has distributed a total of 73.18 billion yuan in dividends since its A-share listing, with 31.94 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Zhifei Biological had 131,600 shareholders, a decrease of 3.17% from the previous period. The average number of circulating shares per shareholder increased by 3.28% to 10,750 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 33.56 million shares, and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [3]. Market Activity - On November 4, 2023, Zhifei Biological's stock price was 21.14 yuan per share, with a trading volume of 3.87 billion yuan and a turnover rate of 1.32%. The total market capitalization stood at 506.05 billion yuan [1]. - The stock has experienced a net inflow of 27.27 million yuan from main funds, with significant buying activity noted in large orders [1].